中药安体维康治疗慢性乙型肝炎临床和实验研究  

Clinical and Experimental Study of Treating Chronic HBV with Antivirus Compound

作　　者：徐向田[1] 李玉英[1] 傅希贤[2] 

机构地区：[1]山东医学高等专科学校,山东省临沂市青年路39号276002 [2]北京大学第一医院

出　　处：《世界中医药》2007年第6期336-338,共3页World Chinese Medicine

基　　金：国家科技部创新基金资助项目;编号:01C26213700154

摘　　要：目的:本研究以中药安体维康(Antivirus Compound,ATVC)进行抗乙型肝炎病毒(HBV)的体外实验和治疗慢性乙型肝炎临床研究。方法:体外实验以HBV-DNA转染细胞系(2.2.15细胞株)为模型。临床治疗慢性乙型肝炎60例,对照组57例,观察治疗3个月和6个月时HBV的复制指标阴转率。结果:体外实验发现ATVC对乙型肝炎表面抗原(HBsAg)和乙型肝炎e抗原(HBeAg)的治疗指数分别为31.75和36.27;对HBV-DNA及其复制中间体成剂量依赖性抑制。临床研究发现ATVC对慢性乙型肝炎治疗组HBeAg和HBV-DNA的转阴率分别为47.8%和54.9%;均高于对照组(P<0.05)。治疗3个月和6个月时的疗效相似。结论:研究表明,ATVC对HBV不论在体内或体外均有明显抑制作用。临床治疗慢性乙型肝炎疗效较好。Objective:The Chinese medicinal known as Antivirus(ATVC) Compound was studied for HBV-fighting action by vitro experiment and clinical research.Method:HBV-DNA transfected cell line(2.2.15 cell strain) were used in vitro experiment.Clinically chronic HBV group(60 cases) and control group(57 cases) were observed for negative conversion rates after three,six month of treatment.Result:therapeutic indexes of ATVC on HBsAg and HBeAg were respectively31.75 and 36.27;and ATVC inhibited HBV-DNA in a dose-dependent manner.Negative conversion rates of HBeAg and HBV-DNA in chronic HBV group were 47.8% and 54.9%,higher than those of the control group(P<0.05).There were little difference between three and six months of treatment.Conclusion:as the research suggested,ATVC apparently inhibit HBV both in vitro and in vivo,and proved satisfying therapeutic effects.

关 键 词：乙型肝炎病毒 慢性乙型肝炎/中医药疗法 @安体维康 

分 类 号：R[医药卫生]